文献
J-GLOBAL ID:201702243762211525
整理番号:17A2006675
回復力:第III相無作為化,局所進行性または転移性HER2陰性乳癌におけるカペシタビンとカペシタビン対プラセボとソラフェニブの比較二重盲検試験【Powered by NICT】
RESILIENCE: Phase III Randomized, Double-Blind Trial Comparing Sorafenib With Capecitabine Versus Placebo With Capecitabine in Locally Advanced or Metastatic HER2-Negative Breast Cancer
著者 (20件):
Baselga Jose
(Memorial Sloan Kettering Cancer Center, New York, NY)
,
Zamagni Claudio
(S. Orsola Malpighi Hospital, Bologna, Italy)
,
Gomez Patricia
(Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology, Barcelona, Spain)
,
Bermejo Begona
(Hospital Clinico Universitario de Valencia, Valencia, Spain)
,
Nagai Shigenori E.
(Saitama Cancer Center, Saitama, Japan)
,
Melichar Bohuslav
(Palacky University Medical School and Teaching Hospital, Olomouc, Czech Republic)
,
Chan Arlene
(Curtin Health Innovation Research Institute, Curtin University, Perth, Australia)
,
Mangel Laszlo
(University of Pecs, Pecs, Hungary)
,
Bergh Jonas
(Karolinska Institutet and University Hospital, Stockholm, Sweden)
,
Costa Frederico
(Hospital Sirio Libanes, Sao Paulo, Brazil)
,
Gomez Henry L.
(Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru)
,
Gradishar William J.
(Northwestern University Feinberg School of Medicine, Chicago, IL)
,
Hudis Clifford A.
(Memorial Sloan Kettering Cancer Center, New York, NY)
,
Rapoport Bernardo L.
(The Medical Oncology Center of Rosebank and Linksfield Park Hospital, Johannesburg, South Africa)
,
Roche Henri
(Institut Claudius Regaud, Toulouse, France)
,
Maeda Patricia
(Bayer HealthCare Pharmaceuticals, Whippany, NJ)
,
Huang Liping
(Bayer HealthCare Pharmaceuticals, Whippany, NJ)
,
Meinhardt Gerold
(Bayer HealthCare Pharmaceuticals, Whippany, NJ)
,
Zhang Joshua
(Bayer HealthCare Pharmaceuticals, Whippany, NJ)
,
Schwartzberg Lee S.
(The West Clinic, Memphis, TN)
資料名:
Clinical Breast Cancer
(Clinical Breast Cancer)
巻:
17
号:
8
ページ:
585-594.e4
発行年:
2017年
JST資料番号:
W3206A
ISSN:
1526-8209
資料種別:
逐次刊行物 (A)
記事区分:
原著論文
発行国:
オランダ (NLD)
言語:
英語 (EN)